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The purpose of this study is to retrospectively evaluate the clinical outcomes and to identify the predictors
ofpatient satisfaction after percutaneous sclerotherapy for venous malformations (VMs) in the extremities.
A totalof 48 patients with VMs in the extremities over 10 years of age underwent sclerotherapy to relieve
symptoms, such as pain, swelling, functional limitations, and cosmetic problems. Self-assessment questionnaires
were sentto rate the degree of symptom improvement and level of satisfaction. Clinical and imaging data
from medicalrecords were analyzed to obtain information about VMs and sclerotherapy. The predictors for
patientsatisfaction were determined by univariate and multivariate analysis of clinical variables. Forty patients
(meanage, 28.2 years; range, 11-69 years) responded to the survey. Sixteen patients had VMs in the upper
extremities, and 24 patients had VMs in the lower extremities. In 12 patients (30%), adjacent bone change was
seen. After amean of 2.6 (range 1-10) sclerotherapy sessions, good response to pain, swelling, dysfunction,
and cosmeticproblems was obtained in 83%, 74%, 79%, and 50% of patients, respectively. Thirty-two patients
(80%) weresatisfied with their outcomes. On univariate analysis, absence of adjacent bone change, maximum
diameter (<6.7 cm), and number of sclerotherapy sessions (<3) were significantly associated with patient
satisfaction.Multivariate analysis revealed absence of adjacent bone change (odds ratio, 7.56; 95% confidence
interval, 1.02-55.8) as an independent predictor for satisfaction. Thus, adjacent bone change significantly
portended adissatisfied patient. In conclusion, percutaneous sclerotherapy was effective to relieve symptoms
of VMs in theextremities, and most patients were satisfied with the outcomes. However, adjacent bone change
was asignificant predictor of patient dissatisfaction.
Keywords: Venous malformation; Sclerotherapy; Extremity; Adjacent bone change; PredictorIntroduction
Venous malformations (VMs) are the most common
type of vascular malformations. VMs are comprised of
dilated, thin walled, sponge-like abnormal channels with
deficient smooth muscle (Mulliken & Glowacki 1982).
They are located in any portion of the body, and the
main locations are the extremities (40%), the head and
neck (40%), and the trunk (20%) (Dubois & Garel 1999).
VMs in the extremities are sometimes asymptomatic but
often present with various symptoms of pain, swelling,* Correspondence: m-nakamura@radiol.med.osaka-u.ac.jp
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in any medium, provided the original work is pfunctional limitations, cosmetic disfigurements, and so
on (Mendonca et al. 2010). Surgery, sclerotherapy, laser
therapy, and conservative treatments such as elastic
compression garments have been used for the management
of VMs (Van der Vleuten et al. 2014). Sclerotherapy
has also played a central role as a minimally invasive
and effective treatment (Van der Vleuten et al. 2014;
Berenguer et al. 1999; Tan et al. 2007).
Not all the outcomes of sclerotherapy for VMs have
been satisfying, however, and overly aggressive treatment
can make the condition worse rather than improve it
and result in serious complications (Lee et al. 2008). A
few studies (Berenguer et al. 1999; Yun et al. 2009) have
evaluated predictors of response after sclerotherapy byis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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clinically useful to help guide patient selection and might
thereby help improve treatment results and minimize
complications. The clinical manifestations of VMs vary
according to anatomic locations. However, predictors for
response to sclerotherapy for extremities VMs have not
yet been identified. The aim of this study was to evaluate
clinical outcomes and predictors for patient satisfaction
after sclerotherapy for VMs in the extremities.
Materials and methods
Patients
Following approval from the Institutional Review Board,
we performed a retrospective study of a clinical database
for 128 patients treated with sclerotherapy in our depart-
ment between December 2002 and May 2012. The inclu-
sion criteria for the present study population were: patients
over 10 years of age who had undergone sclerotherapy for
VMs in the extremities; the sclerotherapy treatment was
considered to be finished; and more than 6 months had
passed since the last treatment. Patients with combined vas-
cular malformations (e.g., capillary VMs, lymphatic VMs,
capillary-lymphatic VMs, Klippel-Trenauney syndrome)
were excluded. Six patients who underwent surgical re-
section after sclerotherapy were also excluded.
VMs were diagnosed by a combination of clinical
examination and noninvasive studies, such as magnetic
resonance imaging (MRI), duplex ultrasonography (US),
and plain film radiography, and were confirmed by
fluoroscopic imaging using direct puncture. The treat-
ment modality was determined by a multidisciplinary
team in our vascular malformation clinic, involving inter-
ventional radiologists, plastic surgeons, orthopedists,
pediatric surgeons, dermatologists, and pathologists. The
indications for invasive treatment included worsening
pain, increased swelling, reduced function, and severe cos-
metic disfigurement, based on balance between the degree
of symptoms and the risk of intervention.
Among 128 patients treated with sclerotherapy, 48
patients who met the inclusion criteria were contacted by
telephone and were sent a questionnaire. Forty patients who
submitted self-assessment data were included in the study.
Procedures
After proper counseling and after obtaining written
informed consent from patients/parents, treatment of
VMs was performed using direct percutaneous injection
of 3% polidocanol, absolute ethanol, or 5% ethanolamine
oleate (EO). Treatment for VMs was typically tailored
to each lesion and to each patient; therefore, it was not
possible to utilize a uniform treatment protocol. As
sclerosants, 3% polidocanol foam was mainly used. When
polidocanol was not effective, we tended to use ethanol or
EO. General anesthesia was used when performingethanol injection. Otherwise, conscious sedation and
local anesthesia were chosen for pain control.
Direct puncture of the lesion was performed using a
21- to 27-gauge needle under ultrasound guidance or by
direct observation. Multiple punctures were performed
to inject sclerosant into the majority of the lesion. The
volume injected was based on the patient’s weight and
on the size of VM. The maximum dose of polidocanol,
ethanol, and EO injected per person was 10 ml, 0.4 ml/kg,
and 0.4 ml/kg, respectively.
The decision to perform repeat sclerotherapy was based
on a discussion with the patient. The goal of treatment
was not to eliminate the lesion, but rather to improve
symptoms. Thus, even if the lesion persistent, treatment
was discontinued if those goals were achieved (Figures 1).
Complications were classified into major or minor com-
plications, according to Society of Interventional Radiology
reporting standards (Omary et al. 2003). Major complica-
tions were those that resulted in an unplanned increase in
the level of care, permanent adverse sequelae, or death.
Minor complications were those that resulted in no seque-
lae with or without nominal therapy requirement.
Questionnaire
A self-assessment questionnaire was sent to the patients in
December 2012. The questionnaire contained items asses-
sing symptoms and satisfaction levels. In the questionnaire,
patients were asked for specific symptoms (e.g., pain, swell-
ing, functional limitations, and cosmetic disfigurements),
and a four-point scale was used to rate the degree of symp-
tom improvement as follows: markedly improved, moder-
ately improved, no change, and worsening (van der Linden
et al. 2009). Similarly, patients were asked whether they
were satisfied with sclerotherapy as follows: very satisfied,
satisfied, dissatisfied, or neither. “Markedly improved” and
“improved” were defined as a “good response”, and “very
satisfied” and “satisfied” were defined as “satisfaction”.
Clinical variables
Data with regard to patient demographics, clinical as-
sessments, imaging studies, treatments, and treatment
complications were obtained from the medical charts
and imaging, as collected by two of the authors (MN
and KO). All patients underwent pre-MRI. Clinical
variables included demographic (sex), and imaging var-
iables (VM location, VM size, VM margin, adjacent
bone change, and anatomical pattern of draining veins
on direct puncture venography), and procedure variables
(the number of sclerotherapy, and sclerosants). Parame-
ters that were proposed as predictors of outcomes in
previous studies were evaluated in the present study
(Berenguer et al. 1999; Puig et al. 2003; Yun et al. 2009;
Jin et al. 2009; Mimura et al. 2009; Mendonca et al. 2010).
Although adjacent bone changes, such as periosteal reaction,
Figure 1 A 30-year-old-male with pain, swelling, and dysfunction of the right knee joint. A. The sagittal fat-saturated T2-weighted MR
image before treatment shows a lobulated high-intensity mass in the suprapatellar bursa. B. Direct puncture phlebography shows the lesion
cavity and the conducting vein (Type 2). Sclerotherapy was performed with 3% polidocanol foam. C. After two sessions, MR imaging shows a
decrease in size and signal intensity of the mass. The patient had improvement of symptoms and indicated satisfaction on the questionnaire.
Table 1 Patient demographics and clinical data



















aData are means. Numbers in parentheses are the range.
bData represent number (percentages) of patients.
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dullary signal change, are often seen in VMs involving deep
tissues (Ly et al. 2003), this change has not been evaluated a
predictors of outcomes in previous reports. Thus, we stud-
ied whether “adjacent bone change” on MRI and plain film
radiography was a predictor of outcomes in our study. The
diameters of lesions were measured using MR images. Based
on MRI, VMs were categorized into two margin types: a
well-defined margin was defined as a sharp transition from
surrounding tissue (n = 17), whereas an ill-defined margin
was defined as an irregular interface with surrounding
tissue (n = 23) (Jin et al. 2009). With regard to anatom-
ical pattern of draining veins on direct puncture ven-
ography, we classified VMs into to the four types; Type
1 – isolated malformation without peripheral drainage,
Type 2 – malformation that drains into normal veins,
Type 3 – malformation that drains into dysplastic
veins, Type 4 – malformation that represents a dyspla-
sia (Puig et al. 2003). In our study, no lesions of Type 4
were included.
Statistical analysis
We evaluated predictors of patient satisfaction, performing
uni- and multivariate analysis of the clinical variables.
The cut-off score for patient age, VM size, and the
number of sclerotherapy treatments were determined by
receiver operating characteristic (ROC) curve analysis.
Univariate analysis was performed to compare variables be-
tween the “satisfaction” group and the “non-satisfaction”
group using the chi-square test and the Kruskal-wallis test.
For multivariate analysis, a binary logistic regression model
was used to identify independent predictors. P values
of less than 0.05 were considered to indicate statisticalsignificance. Statistical analysis was performed using
SPSS Statistics 21 software (IBM Corporation, USA).
Results
Patient demographics and clinical data were summarized
in Table 1. Distribution of the lesions in the extremities
was given in Table 2. A total of 105 treatment sessions
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1–10 sessions). The mean number of punctures per
session was 5.9 (range, 1–27). The sclerosants used for
treatment are listed in Table 1. Polidocanol was used in
a majority (37 of 40) of patients. In five patients, pneu-
matic cuff tourniquets were used beyond the lesion’sFigure 2 A 12-year-old-female with symptoms of pain and swelling of t
and cortical irregularity in the fibula. B. The coronal fat-saturated T2-weight
adjacent to the fibula with diffuse marrow signal abnormality (arrows). C. D
early venous return of the peroneal vein (Type 3). After sclerotherapy with
D. Although the lesion shows a decrease in thickness and signal intensity o
She reported no change in symptoms and indicated dissatisfaction on thevenous outflow. The mean follow-up period was 2.3 years
(range, 7 months-7.5 years).
Two major complications occurred after sclerotherapy.
One patient treated with 10.5 ml of absolute ethanol had
peroneal nerve paralysis for 9 months (Figures 2). The
other patient treated with 20 ml EO had acute renal failure
and needed temporary hemodialysis. Minor complications
like local swelling and pain were experienced in most cases
for a few days and were well controlled with NSAIDs.
Patient self-assessment questionnaire results are given
in Table 3. Before treatment, 36 of the 40 patients (90%)
had disabling pain, 34 (85%) had swelling, 24 (60%) had
functional limitation, and 16 (40%) had cosmetic dis-
figurement. Patients reported “good response” in pain
(83%; 30/36), swelling (74%; 25/34), functional limitation
(80%; 19/24), and cosmetic disfigurement (50%; 8/16).
“Markedly improved” was noted in at least one category in
48% (19 of 40) of patients. None of the patients responded
“worse” for any symptoms. In addition, 32 of 40 patients
(80%) reported being “very satisfied” or “satisfied”
with the treatment; these patients were defined as the
“satisfaction” group.
On univariate analysis of variables to predict satisfaction
with sclerotherapy, absence of adjacent bone change, max-
imum diameter (<6.7 cm), and number of sclerotherapy
sessions (<3) were significantly associated with patient
satisfaction (Table 4).he right calf. A. Radiograph of the right calf demonstrates phleboliths
ed MR image before treatment shows a large and infiltrating mass
irect puncture phlebography reveals VM with dysmorphic veins and
ethanol, the patient had onset of temporary peroneal nerve paralysis.
n MRI, the marrow signal abnormality (arrows) remains unchanged.
questionnaire.
Table 3 Clinical outcomes and degree of satisfaction after sclerotherapy
Symptom Marked improvement Improvement No change Worse Total
Pain 13(36) 17(47) 6(17) 0 36
Swelling 11(32) 14(41) 9(26) 0 34
Functional limitations 10(42) 9(38) 5(20) 0 24
Cosmetic disfigurements 3(19) 5(31) 8(50) 0 16
Very satisfied Satisfied Neither Dissatisfied Total
Satisfaction 16(40) 16(40) 4(10) 4(10) 40
Note. Numbers in parentheses are percentages.
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Absence of adjacent bone change (odds ratio, 7.56;
95% confidence interval, 1.02-55.8) was the only in-
dependent predictor of patient satisfaction. Among
27 (68%) patients with VMs adjacent to the bones,Table 4 Univariate analysis of variables to predict
satisfaction with sclerotherapy





Location of VM 0.333
Upper extremity 14 2
Lower extremity 18 6
Imaging variables
Maximum diameter of VM 0.018
<6.7 cm 19 1
≥6.7 cm 13 7
Margin on MRI 0.055
Limited 16 1
Infiltrating 16 7
Adjacent bone change 0.002
Absent 26 2
Present 6 6
Anatomical pattern of draining veins 0.361
Type 1 19 3
Type 2 8 2
Type 3 5 3
Procedure variables




Polidocanol only 22 4
Other 10 4
aThe Kruskal-wallis test.12 patients (30%) showed the adjacent bone change
(Figures 3).
Discussion
A comprehensive classification of vascular anomalies was ac-
cepted by the International Society for the Study of Vascular
Anomalies (ISSVA) in 1996 (Enjolras & Mulliken 1997).
Two major categories of lesions emerged: vascular tumors
and vascular malformations. Differentiating between
vascular tumors and malformations is essential, as their
clinical, radiological and pathologic features differ. Further,
their associated morbidity and their management are quite
different. VMs are low-flow vascular malformations and
can infiltrate skin, muscles, joints, and sometimes bones.
In 2013, a “modified” Hamburg classification was adopted
to emphasize the importance of extratruncular vs. truncu-
lar sub-types of VMs; ISSVA Classification was reinforced
with an additional review on syndrome-based classification
(Lee et al. 2014). The new classification incorporated
the embryological origin, morphological differences, unique
characteristics, prognosis and recurrence rates of VMs
based on this embryological classification.
Symptoms are dependent on the anatomic location
of the lesion. Pain and swelling are common symptoms
associated with all VMs. With craniofacial lesions, cos-
metic disfigurement may be more debilitating than
functional limitations (Lee & Chen 2005). In contrast,
the management of VMs in the extremities is often dif-
ficult due to functional problems rather than cosmetic
concerns (Mendonca et al. 2010). In this series, 24 patients
(60%) reported functional limitations. Thus, we focused
on VMs in the extremities.
Sclerotherapy is now the primary treatment of choice
for VMs. Several sclerosants have been proven effective
and vary in their mode of action and relative toxicity
(Van der Vleuten et al. 2014). Currently, there is no consen-
sus as to the best sclerosant. All sclerosants are associated
with potential complications, including skin necrosis, per-
ipheral nerve injury, hemoglobinuria, thromboembolism,
infection and delayed muscle fibrosis (Burrows 2013).
We mainly use polidocanol, because it has sufficient
effect and because it is associated with lower major
complication rates (Blaise et al. 2011). Indeed, in our
Table 5 Multivariate analysis of variables to predict
satisfaction with sclerotherapy
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apy using polidocanol.
The efficacy of sclerotherapy for VMs is difficult to
evaluate, as there are no standard assessment criteria
(Rautio et al. 2004). We attempted to evaluate treatment
outcomes according to overall patient satisfaction and
subjective patient response using a self-assessment question-
naire rather than attempt to quantify morphologic responseFigure 3 A 37-year-old-female with symptoms of severe pain of the r
periosteal reaction in the tibia (arrows). B. The axial T2-weighted MR image
irregularity (arrows). C. Direct puncture phlebography reveals VM with normal
with 3% polidocanol foam. D. Although the lesion decreased in size and sign
dissatisfaction on the questionnaire.(van der Linden et al. 2009). This is because lesion sizes
and symptoms of VMs vary widely and there is often dis-
crepancy between the clinical and morphologic responses
to sclerotherapy (Tan et al. 2007; Yun et al. 2009).
Our analysis of a cohort of 40 patients who responded
to follow-up questionnaires showed that 80% of patients
were satisfied with treatment outcome and that only two
major complications (5%) occurred. Pain, swelling, and
functional limitations were improved in about 80% of
patients, whereas cosmetic improvement was seen in
50% of patients. Van der Vleuten et al. (2014) conducted
a systematic review of studies investigating treatment for
VMs. They reported that sclerotherapy was effective in 65%
to 90% of cases. Our results are comparable to those seen in
previous reports and indicate that sclerotherapy was minim-
ally invasive and effective as a primary treatment for VMs.
Identification of predictors of response to sclerotherapy
is important to optimize outcomes through appropriateight lower leg. A. Radiograph of the right lower leg demonstrates tiny
before treatment shows a tiny lesion adjacent to the tibia with cortical
veins and early venous return (Type 2). Sclerotherapy was performed
al intensity on MRI (arrows), she answered no change in symptoms and
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dictors of response to sclerotherapy in VM patients. For
example, Berenguer et al. (1999) reported that male sex
and number of sclerotherapy sessions were independent
predictors of good outcomes. Goyal et al. (2002) proposed
that patients with well defined, small VMs on MRI im-
aging had a better response to sclerotherapy. Yun et al.
(2009) identified no or delayed visualization of drainage
veins, a well-defined margin on MRI, and female sex as
predictors of good outcomes. Mimura et al. (2009) revealed
a better therapeutic effect in patients with small VMs,
well-defined VMs, and VMs with good stasis of sclero-
sant during sclerotherapy.
In our study, adjacent bone change, maximum diameter
of VM, and number of sclerotherapy sessions were signifi-
cantly associated with patient satisfaction on univariate
analysis. Multivariate analysis revealed that absence of
adjacent bone change was an independent predictor for
good satisfaction after sclerotherapy, whereas sex, VM
location, VM margin, and anatomical pattern of drain-
ing veins on a venography were not. Thus, poor out-
comes are expected in VMs with adjacent bone change.
Mendonca et al. (2010) estimated that VMs with bone
or joint involvement were associated with a higher risk
of symptom recurrence. Goto et al. (2001) reported that
hemangiomas with adjacent periosteal new bone formation
were more painful than those without it. These results
support our findings.
Bone changes adjacent to VMs (also referred to as
“soft-tissue hemangiomas” in the literature) were ob-
served in 19-63% of patients on plain film or MRI
(Mendonca et al. 2010; Ly et al. 2003; Goto et al. 2001;
Sung et al. 1998; Enjolras et al. 1997; Breugem et al.
2001; Pourbagher et al. 2011). In our cohort, 12 patients
(30%) had bone changes adjacent to VMs. The precise
mechanism of adjacent bone change remains unknown.
Several factors could contribute to adjacent bone change,
including physical irritation, an extrinsic pressure and
passive hyperemia (Sung et al. 1998; Goto et al. 2001;
Pourbagher et al. 2011). Bone homeostasis is maintained
by the balance between bone resorption and formation
and is affected by local oxygen tension and pH, various
cytokines, and hormones (Arnett 2010). We postulate
that some cytokines and the change in local oxygen ten-
sion and pH due to latent microshunts and congestion
may be one of the important factors developing the ad-
jacent bone change around VMs, but it is still no better
than a conjecture.
Further investigation is needed to clarify the effect of
adjacent bone change on patient symptoms that may im-
pair patient satisfaction to sclerotherapy. Studies of local
oxygen tension and pH, bone metabolic markers of
osteoblast and osteoclast function, and some cytokines
might be useful in this regard.This study had several limitations. First, the study was
retrospective and had a small number of patients. Further,
there were no standards for treatment indication and evalu-
ation criteria for sclerotherapy of VMs. In addition, we did
not evaluate patient mental health that may affect patient
satisfaction. We may take account of the use of validated
quality-of-life assessment tool, such as SF-36 and the Child
Health Questionnaire (CHQ).
In conclusion, percutaneous sclerotherapy was effective
in relieving symptoms in patients with VMs in the extrem-
ities. Adjacent bone change was a significant predictor of
patient dissatisfaction.
Competing interest
The authors declare that they have no competing ineterset.
Authors’ contribution
All authors read and approved the final manuscript.
Author details
1Department of Diagnostic and Interventional Radiology, Osaka University
Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan.
2Department of Orthopedic Surgery, Osaka University Graduate School of
Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan. 3Department of
Orthopedic Surgery, Osaka Medical Center for Cancer and Cardiovascular
Diseases, 1-3-3 Nakmichi Higashinari, Osaka 537-8511, Japan. 4Department of
Pediatric Surgery, Osaka University Graduate School of Medicine, 2-2
Yamadaoka Suita, Osaka 565-0871, Japan.
Received: 30 June 2014 Accepted: 3 September 2014
Published: 11 September 2014
References
Arnett TR (2010) Acidosis, hypoxia and bone. Arch Biochem Biophys 503:103–109
Berenguer B, Burrows PE, Zurakowski D, Mulliken JB (1999) Sclerotherapy of
craniofacial venous malformations: complications and results. Plast Reconstr
Surg 104:1–11, discussion 12–5
Blaise S, Charavin-Cocuzza M, Riom H, Brix M, Seinturier C, Diamand JM, Gachet
G, Carpentier PH (2011) Treatment of low-flow vascular malformations by
ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and
literature review. Eur J Vasc Endovasc Surg 41:412–417
Breugem CC, Maas M, van der Horst CM (2001) Magnetic resonance imaging
findings of vascular malformations of the lower extremity. Plast Reconstr
Surg 108:878–884
Burrows PE (2013) Endovascular treatment of slow-flow vascular malformations.
Tech Vasc Interv Radiol 16:12–21
Dubois J, Garel L (1999) Imaging and therapeutic approach of hemangiomas and
vascular malformations in the pediatric age group. Pediatr Radiol 29:879–893
Enjolras O, Mulliken JB (1997) Vascular tumors and vascular malformations (new issues).
Adv Dermatol 13:375–423
Enjolras O, Ciabrini D, Mazoyer E, Laurian C, Herbreteau D (1997) Extensive pure
venous malformations in the upper or lower limb: a review of 27 cases.
J Am Acad Dermatol 36:219–225
Goto T, Kojima T, Iijima T, Yokokura S, Kawano H, Yamamoto A, Matsuda K (2001)
Soft-tissue haemangioma and periosteal new bone formation on the
neighbouring bone. Arch Orthop Trauma Surg 121:549–553
Goyal M, Causer PA, Armstrong D (2002) Venous vascular malformations in
pediatric patients: comparison of results of alcohol sclerotherapy with
proposed MR imaging classification. Radiology 223:639–644
Jin Y, Lin X, Chen LW, Hu X, Ma G, Zhu L, Sun M, Yang C, Wang W (2009)
Craniofacial venous malformations: magnetic resonance imaging features
that predict treatment outcome. J Oral Maxillofac Surg 67:2388–2396
Lee CH, Chen SG (2005) Direct percutaneous ethanol instillation for treatment of
venous malformation in the face and neck. Br J Plast Surg 58:1073–1078
Lee KB, Kim DI, Oh SK, Do YS, Kim KH, Kim YW (2008) Incidence of soft tissue
injury and neuropathy after embolo/sclerotherapy for congenital vascular
malformation. J Vasc Surg 48:1286–1291
Nakamura et al. SpringerPlus 2014, 3:520 Page 8 of 8
http://www.springerplus.com/content/3/1/520Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, Huang Y,
Laredo J, Loose DA, Markovic J, Mattassi R, Parsi K, Rabe E, Rosenblatt M,
Shortell C, Stillo F, Vaghi M, Villavicencio L, Zamboni P (2014) Guideline.
Diagnosis and treatment of venous malformations. consensus document of
the international union of phlebology (iup): updated-2013. Int Angiol,
http://www.minervamedica.it/en/journals/international-angiology/article.php?
cod=R34Y9999N00A140001. Accessed 10 Sep 2014
Ly JQ, Sanders TG, Mulloy JP, Soares GM, Beall DP, Parsons TW, Slabaugh MA
(2003) Osseous change adjacent to soft-tissue hemangiomas of the
extremities: correlation with lesion size and proximity to bone. AJR Am J
Roentgenol 180:1695–1700
Mendonca DA, McCafferty I, Nishikawa H, Lester R (2010) Venous malformations
of the limbs: the Birmingham experience, comparisons and classification in
children. J Plast Reconstr Aesthet Surg 63:383–389
Mimura H, Fujiwara H, Hiraki T, Gobara H, Mukai T, Hyodo T, Iguchi T, Yasui K,
Kimata Y, Kanazawa S (2009) Polidocanol sclerotherapy for painful venous
malformations: evaluation of safety and efficacy in pain relief. Eur Radiol
19:2474–2480
Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in
infants and children: a classification based on endothelial characteristics. Plast
Reconstr Surg 69:412–422
Omary RA, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg MS, Sacks D, Rholl
KS, Meranze SG, Lewis CA (2003) Quality improvement guidelines for the
reporting and archiving of interventional radiology procedures. J Vasc Interv
Radiol 14(9 Pt 2):S293–S295
Pourbagher A, Pourbagher MA, Karan B, Ozkoc G (2011) MRI manifestations of
soft-tissue haemangiomas and accompanying reactive bone changes.
Br J Radiol 84:1100–1108
Puig S, Aref H, Chigot V, Bonin B, Brunelle F (2003) Classification of venous
malformations in children and implications for sclerotherapy. Pediatr Radiol
33:99–103
Rautio R, Saarinen J, Laranne J, Salenius JP, Keski-Nisula L (2004) Endovascular
treatment of venous malformations in extremities: results of sclerotherapy
and the quality of life after treatment. Acta Radiol 45:397–403
Sung MS, Kang HS, Lee HG (1998) Regional bone changes in deep soft tissue
hemangiomas: radiographic and MR features. Skeletal Radiol 27:205–210
Tan KT, Kirby J, Rajan DK, Hayeems E, Beecroft JR, Simons ME (2007) Percutaneous
sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular
malformations: a single-center experience. J Vasc Interv Radiol 18:343–351
van der Linden E, Pattynama PM, Heeres BC, De Jong SC, Hop WC, Kroft LJ (2009)
Long-term patient satisfaction after percutaneous treatment of peripheral
vascular malformations. Radiology 251:926–932
Van der Vleuten CJ, Kater A, Wijnen MH, Schultze Kool LJ, Rovers MM (2014)
Effectiveness of sclerotherapy, surgery, and laser therapy in patients with
venous malformations: a systematic review. Cardiovasc Intervent Radiol
37:977–989
Yun WS, Kim YW, Lee KB, Kim DI, Park KB, Kim KH, Do YS, Lee BB (2009)
Predictors of response to percutaneous ethanol sclerotherapy (PES) in
patients with venous malformations: analysis of patient self-assessment and
imaging. J Vasc Surg 50:589.e1–9
doi:10.1186/2193-1801-3-520
Cite this article as: Nakamura et al.: Percutaneous sclerotherapy for
venous malformations in the extremities: clinical outcomes and
predictors of patient satisfaction. SpringerPlus 2014 3:520.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
